COYANasdaqPharmaceutical PreparationsFiscal year ends December 31

Coya Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$4.20−0.05 (-1.18%)

Close on Oct 19, 2026

Market cap: $98.52M
P/E (TTM): –
Dividend yield: –

Coya Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cash & Equivalents	47	38	33	5.93	4.34	–
Cash & Short-Term Investments	47	38	33	5.93	4.34	–
Prepaid Expenses & Other	3.12	5.97	1.07	1.25	0.24	–
Total Current Assets	50	44	41	7.18	4.58	–
Property, Plant & Equipment	0.01	0.04	0.07	0.09	0.12	–
Gross Property, Plant & Equipment	–	0.14	0.14	0.14	0.14	–
Accumulated Depreciation	–	-0.10	-0.07	-0.04	-0.02	–
Total Assets	50	44	41	8.40	4.79	–
Accounts Payable	1.06	1.59	1.16	1.82	0.86	–
Accrued Expenses	3.61	1.39	2.97	2.01	0.29	–
Current Income Taxes Payable	–	–	0.72	–	–	–
Deferred Revenue (Current)	1.20	0.85	0.92	–	–	–
Total Current Liabilities	5.87	3.82	5.05	3.82	1.15	–
Total Liabilities	6.92	4.77	5.63	17	1.15	–
Preferred Stock	–	–	–	8.79	8.79	–
Common Stock	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	105	80	62	0.68	0.47	–
Retained Earnings	-62	-41	-26	-18	-5.62	–
Shareholders' Equity	43	40	36	-8.39	3.64	8.30
Total Equity	43	40	36	-8.39	3.64	8.30
Total Liabilities & Equity	50	44	41	8.40	4.79	–
Shares Outstanding(shares)	21	17	14	2.59	2.59	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -288.7%
Net margin: -270.2%
Return on equity, FY2025: -51.4%

Financial strength

Current ratio: 13.40
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1229.4%

Valuation

P/E ratio: –
Price to sales: 12.29
Price to book: 2.28
Dividend yield: –